UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 15, 2009
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Florida
|
|
000-33357
|
|
65-0643773 |
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 2 Snunit Street |
|
|
| Science Park, POB 455 |
|
|
| Carmiel, Israel
|
|
20100 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On October 15, 2009, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release
announcing positive top-line results from the Company’s pivotal Phase III clinical trial of UPLYSO
(taliglucerase alfa) in treatment naive patients diagnosed with Gaucher disease. A copy of the
press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press release dated October 15, 2009.
2